J&J Anti-Fungal Tablet Draws FDA Liver-Damage Warnings

Johnson & Johnson’s anti-fungal Nizoral tablets raise the risk of deadly liver injuries and harmful drug interactions and their use should be limited, regulators in the U.S. and European Union said.

The U.S. Food and Drug Administration said in a statement today that it changed the drug’s label to warn that Nizoral tablets shouldn’t be the first line of treatment for a fungal infection. The European Medicines Agency, meanwhile, said it was recommending a suspension of marketing for oral treatments containing ketoconazole, Nizoral’s main ingredient.